CAS 168079-32-1: Lixivaptan
Description:Lixivaptan is a selective vasopressin V2 receptor antagonist, primarily used in the treatment of conditions associated with excessive vasopressin, such as hyponatremia and certain forms of heart failure. It functions by inhibiting the action of vasopressin on the kidneys, leading to increased water excretion without significant electrolyte loss. This mechanism helps to correct fluid imbalances in patients. Lixivaptan is characterized by its chemical structure, which includes a specific arrangement of atoms that contributes to its pharmacological activity. It is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. The substance is also noted for its relatively low potential for drug interactions, making it a suitable option for patients on multiple medications. As with any medication, potential side effects may include dehydration, hypotension, and electrolyte imbalances, necessitating careful monitoring during treatment. Overall, lixivaptan represents a targeted approach to managing disorders related to vasopressin dysregulation.
Formula:C27H21ClFN3O2
InChI:InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
InChI key:InChIKey=PPHTXRNHTVLQED-UHFFFAOYSA-N
SMILES:O=C(NC1=CC=C(C(Cl)=C1)C(=O)N2C=3C=CC=CC3CN4C=CC=C4C2)C5=CC(F)=CC=C5C
- Synonyms:
- Benzamide, N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl-
- N-[3-Chloro-4-(10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-10-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide
- N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide
- Vpa-985
- Way-Vpa-985
- Lixivaptan